Clinical Trials of Niclosamide, Repurposed Drug For COVID-19 Treatment, Initiated by CSIR India & Laxai Life Sciences

CSIR India and Laxai Life Sciences on Sunday initiated clinical trials of repurposed drug Niclosamide for COVID-19 treatment. The Ministry of Science and Technology said, "The trial is multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of the drug."

Coronavirus | Representational Image (Photo Credits: ANI)

Clinical Trials of Niclosamide, Repurposed Drug For COVID-19 Treatment, Initiated by CSIR India & Laxai Life Sciences: 

(SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter, Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)

Share Now